DelveInsight reports,Bone and Joint Infections - Market Insights, Epidemiology, and Market Forecasts - 2032 (https://www.delveinsight.com/report-store/bone-and-joint-infection-market?utm_source=reportutm_medium=promotionutm_campaign=hpr) provides a detailed analysis of bone and joint infections, including historical and projected epidemiology, market trends in the US, EU5 countries (Germany, Spain, Italy, France, UK), and Japan.
Key highlights of the Bone and Joint Infections market report:
- The 7MM bone and joint infections market is expected to grow steadily at a notable CAGR by 2032.
- Although osteomyelitis is estimated to affect fewer than 25 people per 100,000 people per year, studies show that the incidence in hospitalized patients is much higher, with rates as high as 1 in 675 hospitalizations.
- The BioFire Joint Infection Panel (JI Panel) received FDA approval in 2022. This multiplex PCR assay targets 39 pathogens including selected Gram-positive and Gram-negative bacteria, yeast, and antimicrobial resistance genes to detect common bone and joint pathogens.
- Performance evaluation of the JI panel was performed retrospectively using 63 frozen residual joint fluid specimens and prospectively using 104 anonymized specimens, all examined within 1 week of collection.
- Some of the prominent drugs in the bone and joint infections market include Afavicin, Omadacycline Pills, SCT650C, Bimekizumab, Secukinumab, Upadacitinib, Jactinib, Filgotinib, Ixekizumab, etc.
- Leading companies in the bone and joint infection field include the Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Debiopharm International SA, Sinoceltech, Inc., UCB Biopharma SRL, Biocad, Novartis Pharmaceuticals, AbbVie, Ghent University Hospital, Suzhou Zergen Biopharmaceuticals Co., Ltd., Tasly Pharmaceutical Group Co., Ltd., and Asia Cell Therapeutics. (Shanghai) Co., Ltd., Akeso, Alfasigma S.p.A., Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd., Eli Lilly and Company, etc.
Click here to learn more about the osteoarthritis market outlook, drug intake, treatment status, and epidemiological trends. Bone and joint infections market forecast
Overview of Bone and Joint Infections
Bone and joint infections (BJIs), such as osteomyelitis (bone infections) and septic arthritis (joint infections), are serious conditions that are often caused by bacterial pathogens, such as: Staphylococcus aureus and streptococci seed. These infections can result from direct contamination, such as through surgery, injury, or bloodstream infections, or from the spread of nearby infections. BJI is of particular concern for people who are immunocompromised, have diabetes, or have artificial joints implanted.
Early diagnosis and prompt treatment are essential to prevent complications such as bone destruction, chronic infection, and joint dysfunction. Standard treatment usually includes long-term antibiotic therapy and, in severe cases, surgery to remove infected tissue. Continuing advances in diagnostics, antimicrobial treatments, and surgical techniques continue to improve patient outcomes, making the bone and joint infections market an important area for medical research and pharmaceutical innovation.
Epidemiology of bone and joint infections
The epidemiology section of the report provides insights into the historical, current, and projected trends of bone and joint infections in seven major markets (7MM) from 2019 to 2032. Through various studies and expert opinions, factors contributing to these trends are identified. This section also provides a detailed analysis of the diagnosed patient population and future trends.
Download the report to explore the drivers behind epidemiological trends in bone and joint infections. Epidemiological prediction of bone and joint infections
Drug uptake and pipeline development for bone and joint infections
The drug uptake section of the report assesses the uptake rate of newly launched or soon to be launched drugs in the osteoarthritis market. Provides analysis of market uptake, patient uptake by therapies, and drug sales.
Additionally, the therapeutic drug evaluation section highlights the fastest-taking drugs and the reasons behind their popularity. It also includes a comparative analysis of drugs based on market share.
This report also provides an in-depth look at pipeline development activity in bone and joint infections, providing insight into various therapeutic candidates at various stages of development. Analyze recent alliances, mergers, acquisitions, patent licensing, and other related activity regarding emerging therapies.
Strengths of the bone and joint infections market
- Continuing research into new antibiotics and surgical procedures is improving the treatment of bone and joint infections.
- Increasing awareness among healthcare providers and advances in diagnostic technology have enabled earlier detection and better management of infections.
Weaknesses of the Bone and Joint Infections Market
- The increase in multidrug-resistant bacterial strains complicates effective treatment and poses a significant challenge to infectious disease control.
- The financial burden of prolonged antibiotic treatment, surgical intervention, and hospitalization makes treatment costly for both patients and the healthcare system.
Bone and Joint Infections Market Report Scope
- Study period: 2019-2032
- coverage: 7MM [USA, 5 EU countries (Germany, France, Italy, Spain, UK), Japan]
- major companies：Harbor-UCLA Medical CenterのLundquist Institute for Biomedical Innovation、Debiopharm International SA、Sinocelltech Ltd.、UCB Biopharma SRL、Biocad、Novartis Pharmaceuticals、AbbVie、University Hospital Ghent、Suzhou Zelgen Biopharmaceuticals Co., Ltd.など。
- Main treatments: Afavicin, omadacycline tablets, SCT650C, bimekizumab, secukinumab, upadacitinib, jactinib, filgotinib, ixekizumab, etc.
- therapeutic evaluation: Overview of commercially available and emerging treatments for bone and joint infections.
- market trends: Drivers and barriers impacting the Bone and Joint Infections market.
- competitive intelligence: SWOT analysis, PESTLE analysis, Porter's five forces, BCG matrix, market entry strategy.
- unmet needs: Key opinion leader (KOL) views, analyst insights, market access and reimbursement details.
To learn more about the key players and advances in the current state of bone and joint infection treatment, please visit: Bone and Joint Infections Market Analysis Report
table of contents
- Bone and Joint Infections Market Report Overview
- Overview of Bone and Joint Infections
- SWOT analysis of bone and joint infections
- Overview of proportion (%) of patients with bone and joint infections
- Bone and Joint Infections Market Overview
- Background and overview of bone and joint infections
- Epidemiology and patient population of bone and joint infections
- Number of patients with bone and joint infections by country
- Current treatments and medical practices for bone and joint infections
- Unmet needs in bone and joint infections
- New treatments for bone and joint infections
- Bone and Joint Infections Market Outlook
- Bone and joint infections market analysis by country (2019-2032)
- Market Access and Treatment Reimbursement for Bone and Joint Infections
- Bone and Joint Infections Market Drivers
- Bone and Joint Infections Market Barriers
- Bone and Joint Infections Appendix
- How to report bone and joint infections
- DelveInsight Features
- Disclaimer
- About DelveInsight
About DelveInsight
DelveInsight is a leading healthcare business consultant and market research firm specializing in life sciences. We support pharmaceutical companies by providing comprehensive end-to-end solutions to improve their performance.
We also provide healthcare consulting services that help you analyze the market to accelerate business growth and overcome challenges with a practical approach.
Contact information:
Himanshu
hmason@delveinsight.com
info@delveinsight.com
+14699457679
